XNAS
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -1.13 | -1.06 | +6.19% | $0 | ✅ Beat | -0.40% | -6.91% | — |
| 2026-03-02 | Q4 2025 | -1.04 | -1.03 | +0.96% | $0 | ✅ Beat | -1.36% | +5.68% | +18.79% |
| 2025-11-10 |
| Q3 2025 |
| -1.15 |
| -1.11 |
| +3.48% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -1.03 | -1.13 | -9.71% | $0 | ❌ Miss | +0.00% | +6.49% | +8.20% |
| 2025-03-03 | Q4 2024 | -1.11 | -1.19 | -7.21% | $0 | ❌ Miss | -3.25% | +19.59% | +20.52% |
| 2024-08-12 | Q2 2024 | -0.60 | -0.60 | +0.00% | $0 | ➖ Inline | -0.11% | +12.55% | +13.86% |
| 2024-05-13 | Q1 2024 | -0.61 | -0.64 | -4.92% | $0 | ❌ Miss | +2.41% | -0.59% | -15.97% |
| 2024-03-05 | Q4 2023 | -0.49 | -0.32 | +34.69% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.